ReviewMolecular diagnosis & therapy2024
Advances in Radioligand Theranostics in Oncology.
Review in Molecular diagnosis & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Clinicopathological features and therapeutic advances in primary pulmonary lymphoepithelioma-like carcinoma (Review).Oncology letters · 2026Review
- Multimodal strategies for diagnosing and treating thyroid cancer: Advances in basic and clinical research.Translational oncology · 2026Review
- Early Side Effects of rhTSH-Aided Radioiodine Ablation and Treatment of Differentiated Thyroid Cancer: A Real-World Experience.World journal of nuclear medicine · 2026Article
- Brain Cancer: Molecular Alterations and Emerging Trends in Neuropharmacology.International journal of molecular sciences · 2026Review
- Article
- A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [EJNMMI radiopharmacy and chemistry · 2026Article
- Review
- Targeted Nanoboron Delivery Platform for Boron Neutron Capture Therapy in Refractory Solid Tumors.International journal of nanomedicine · 2026Review
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025Review
- Development of aCellular oncology (Dordrecht, Netherlands) · 2025Article
- Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects.World journal of nuclear medicine · 2025Review
- A Narrative Review of Theranostics in Neuro-Oncology: Advancing Brain Tumor Diagnosis and Treatment Through Nuclear Medicine and Artificial Intelligence.International journal of molecular sciences · 2025Review
- Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.International journal of molecular sciences · 2025Review
- Review
- Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.European journal of nuclear medicine and molecular imaging · 2025Article
- Prostate-Specific Membrane Antigen-Positron Emission Tomography-Guided Radiomics and Machine Learning in Prostate Carcinoma.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Theranostics with radioligands (radiotheranostics) has played a pivotal role in oncology. Radiotheranostics explores the molecular targets expressed on tumor cells to target them for imaging and therapy. In this way, radiotheranostics entails non-invasive demonstration of the in vivo expression of a molecular target of interest through imaging followed by the administration of therapeutic radioligand targeting the tumor-expressed molecular target. Therefore, radiotheranostics ensures that only patients with a high likelihood of response are treated with a particular radiotheranostic agent, ensuring the delivery of personalized care to cancer patients. Within the last decades, a couple of radiotheranostics agents, including Lutetium-177 DOTATATE (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.